Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center
Background: One of the FDA-approved treatments for COVID-19 is remdesivir. In this study, we investigated adverse drug events (ADEs) of remdesivir in COVID-19 patients who contacted 13-Aban pharmacy's drug and poison information center (DPIC). Methods: In this study, data of patients receiving...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center for Rational Use of Drugs (RCRUD)
2023-09-01
|
| Series: | Journal of Pharmaceutical Care |
| Subjects: | |
| Online Access: | https://jpc.tums.ac.ir/index.php/jpc/article/view/590 |